Skip to main content
Top
Published in: BMC Infectious Diseases 1/2011

Open Access 01-12-2011 | Research article

Impact of routine PCV7 (Prevenar) vaccination of infants on the clinical and economic burden of pneumococcal disease in Malaysia

Authors: Syed Aljunid, Gulifeiya Abuduxike, Zafar Ahmed, Saperi Sulong, Amrizal Muhd Nur, Adrian Goh

Published in: BMC Infectious Diseases | Issue 1/2011

Login to get access

Abstract

Background

Pneumococcal disease is the leading cause of vaccine-preventable death in children younger than 5 years of age worldwide. The World Health Organization recommends pneumococcal conjugate vaccine as a priority for inclusion into national childhood immunization programmes. Pneumococcal vaccine has yet to be included as part of the national vaccination programme in Malaysia although it has been available in the country since 2005. This study sought to estimate the disease burden of pneumococcal disease in Malaysia and to assess the cost effectiveness of routine infant vaccination with PCV7.

Methods

A decision model was adapted taking into consideration prevalence, disease burden, treatment costs and outcomes for pneumococcal disease severe enough to result in a hospital admission. Disease burden were estimated from the medical records of 6 hospitals. Where local data was unavailable, model inputs were obtained from international and regional studies and from focus group discussions. The model incorporated the effects of herd protection on the unvaccinated adult population.

Results

At current vaccine prices, PCV7 vaccination of 90% of a hypothetical 550,000 birth cohort would incur costs of RM 439.6 million (US$128 million). Over a 10 year time horizon, vaccination would reduce episodes of pneumococcal hospitalisation by 9,585 cases to 73,845 hospitalisations with cost savings of RM 37.5 million (US$10.9 million) to the health system with 11,422.5 life years saved at a cost effectiveness ratio of RM 35,196 (US$10,261) per life year gained.

Conclusions

PCV7 vaccination of infants is expected to be cost-effective for Malaysia with an incremental cost per life year gained of RM 35,196 (US$10,261). This is well below the WHO's threshold for cost effectiveness of public health interventions in Malaysia of RM 71,761 (US$20,922).
Appendix
Available only for authorised users
Literature
1.
go back to reference Hausdorff WP, Bryant J, Paradiso PR, Siber GR: Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis. 2000, 30: 100-121. 10.1086/313608.CrossRefPubMed Hausdorff WP, Bryant J, Paradiso PR, Siber GR: Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis. 2000, 30: 100-121. 10.1086/313608.CrossRefPubMed
2.
go back to reference Isaacman DJ, McIntosh ED, Reinert RR: Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines. Int J Infect Dis. 2010, 14: e197-209.CrossRefPubMed Isaacman DJ, McIntosh ED, Reinert RR: Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines. Int J Infect Dis. 2010, 14: e197-209.CrossRefPubMed
3.
go back to reference Lin TY, Shah NK, Brooks D, Garcia CS: Summary of invasive pneumococcal disease burden among children in the Asia-Pacific region. Vaccine. 2010, 28: 7589-7605. 10.1016/j.vaccine.2010.07.053.CrossRefPubMed Lin TY, Shah NK, Brooks D, Garcia CS: Summary of invasive pneumococcal disease burden among children in the Asia-Pacific region. Vaccine. 2010, 28: 7589-7605. 10.1016/j.vaccine.2010.07.053.CrossRefPubMed
4.
go back to reference Gil-Prieto R, García-García L, Alvaro-Meca A, Méndez C, García A, de Miguel AG: The burden of hospitalisations for community-acquired pneumonia (CAP) and pneumococcal pneumonia in adults in Spain (2003-2007). Vaccine. 2011, 412-416. 29 Gil-Prieto R, García-García L, Alvaro-Meca A, Méndez C, García A, de Miguel AG: The burden of hospitalisations for community-acquired pneumonia (CAP) and pneumococcal pneumonia in adults in Spain (2003-2007). Vaccine. 2011, 412-416. 29
5.
go back to reference Centers for Disease Control and Prevention: Epidemiology and Prevention of Vaccine-Preventable Diseases. 2011, Washington DC: Public Health Foundation, 12 Centers for Disease Control and Prevention: Epidemiology and Prevention of Vaccine-Preventable Diseases. 2011, Washington DC: Public Health Foundation, 12
6.
go back to reference World Health Organization: Pneumococcal conjugate vaccine for childhood immunization - WHO position paper. Wkly Epidemiol Record. 2007, 82: 93-104. World Health Organization: Pneumococcal conjugate vaccine for childhood immunization - WHO position paper. Wkly Epidemiol Record. 2007, 82: 93-104.
8.
go back to reference Jover F, Cuadrado JM, Andreu L, Martínez S, Cañizares R, de la Tabla VO, Martin C, Roig P, Merino J: A comparative study of bacteremic and non-bacteremic pneumococcal pneumonia. Eur J Intern Med. 2008, 19: 15-21. 10.1016/j.ejim.2007.03.015.CrossRefPubMed Jover F, Cuadrado JM, Andreu L, Martínez S, Cañizares R, de la Tabla VO, Martin C, Roig P, Merino J: A comparative study of bacteremic and non-bacteremic pneumococcal pneumonia. Eur J Intern Med. 2008, 19: 15-21. 10.1016/j.ejim.2007.03.015.CrossRefPubMed
9.
go back to reference World Health Organization: Pneumococcal vaccines. Wkly Epidemiol Record. 2003, 14: 110-19. World Health Organization: Pneumococcal vaccines. Wkly Epidemiol Record. 2003, 14: 110-19.
10.
go back to reference Levine OS, O'Brien KL, Knoll M, Adegbola RA, Black S, Cherian T, Dagan R, Goldblatt D, Grange A, Greenwood B, Hennessy T, Klugman KP, Madhi SA, Mulholland K, Nohynek H, Santosham M, Saha SK, Scott JA, Sow S, Whitney CG, Cutts F: Pneumococcal vaccination in developing countries. Lancet. 2006, 367 (9526): 1880-1882. 10.1016/S0140-6736(06)68703-5.CrossRefPubMed Levine OS, O'Brien KL, Knoll M, Adegbola RA, Black S, Cherian T, Dagan R, Goldblatt D, Grange A, Greenwood B, Hennessy T, Klugman KP, Madhi SA, Mulholland K, Nohynek H, Santosham M, Saha SK, Scott JA, Sow S, Whitney CG, Cutts F: Pneumococcal vaccination in developing countries. Lancet. 2006, 367 (9526): 1880-1882. 10.1016/S0140-6736(06)68703-5.CrossRefPubMed
11.
go back to reference Centers for Disease Control and Prevention: Vaccine preventable deaths and the global immunization vision and strategy, 2006-2015. MMWR Morb Mortal Wkly Rep. 2006, 55: 511-515. Centers for Disease Control and Prevention: Vaccine preventable deaths and the global immunization vision and strategy, 2006-2015. MMWR Morb Mortal Wkly Rep. 2006, 55: 511-515.
13.
14.
go back to reference Levine OS, Knoll MD, Jones A, Walker DG, Risko N, Gilani Z: Global status of Haemophilus influenzae type b and pneumococcal conjugate vaccines: evidence, policies, and introductions. Curr Opin Infect Dis. 2010, 236-241. 23 Levine OS, Knoll MD, Jones A, Walker DG, Risko N, Gilani Z: Global status of Haemophilus influenzae type b and pneumococcal conjugate vaccines: evidence, policies, and introductions. Curr Opin Infect Dis. 2010, 236-241. 23
15.
go back to reference John TJ, Samuel R: Herd immunity and herd effect: new insights and definitions. Eur J Epidemiol. 2000, 16: 601-606. 10.1023/A:1007626510002.CrossRefPubMed John TJ, Samuel R: Herd immunity and herd effect: new insights and definitions. Eur J Epidemiol. 2000, 16: 601-606. 10.1023/A:1007626510002.CrossRefPubMed
16.
go back to reference Fox JP, Elveback L, Scott W, Gatewood L, Ackerman E: Herd Immunity: basic concept and relevance to public health immunization practices. Am J Epidemiol. 1971, 94: 179-189.PubMed Fox JP, Elveback L, Scott W, Gatewood L, Ackerman E: Herd Immunity: basic concept and relevance to public health immunization practices. Am J Epidemiol. 1971, 94: 179-189.PubMed
17.
go back to reference Plotkin S, Fine P, Eames K, Heyman DL: "Herd Immunity":A Rough Guide. Clin Infect Dis. 2001, 52: 911-916. Plotkin S, Fine P, Eames K, Heyman DL: "Herd Immunity":A Rough Guide. Clin Infect Dis. 2001, 52: 911-916.
18.
go back to reference O'Brien KL, Dagan R: The potential Indirect effect of conjugate pneumococcal vaccine. Vaccine. 2003, 21: 1815-1825. 10.1016/S0264-410X(02)00807-1.CrossRefPubMed O'Brien KL, Dagan R: The potential Indirect effect of conjugate pneumococcal vaccine. Vaccine. 2003, 21: 1815-1825. 10.1016/S0264-410X(02)00807-1.CrossRefPubMed
19.
go back to reference Centers for Disease Control and Prevention: Direct and Indirect Effects of Routine Vaccination of Children with 7-Valent Pneumococcal Conjugate Vaccine on Incidence of Invasive Pneumococcal Disease --- United States, 1998--2003. MMWR Morb Mortal Wkly Rep. 2005, 54: 893-897. Centers for Disease Control and Prevention: Direct and Indirect Effects of Routine Vaccination of Children with 7-Valent Pneumococcal Conjugate Vaccine on Incidence of Invasive Pneumococcal Disease --- United States, 1998--2003. MMWR Morb Mortal Wkly Rep. 2005, 54: 893-897.
20.
go back to reference Lexau CA, Lynfield R, Danila R, Pilishvili T, Facklam R, Farley MM, Harrison LH, Schaffner W, Reingold A, Bennett NM, Hadler J, Cieslak PR, Whitney CG, Active Bacterial Core Surveillance Team: Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA. 2005, 294: 2043-2051. 10.1001/jama.294.16.2043.CrossRefPubMed Lexau CA, Lynfield R, Danila R, Pilishvili T, Facklam R, Farley MM, Harrison LH, Schaffner W, Reingold A, Bennett NM, Hadler J, Cieslak PR, Whitney CG, Active Bacterial Core Surveillance Team: Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA. 2005, 294: 2043-2051. 10.1001/jama.294.16.2043.CrossRefPubMed
21.
go back to reference Metlay JP, Fishman NO, Joffe M, Edelstein PH: Impact of pediatric vaccination with pneumoccal conjugate vaccine on the risk of bacteremic pneumococcal pneumonia in adults. Vaccine. 2006, 24: 468-475. 10.1016/j.vaccine.2005.07.095.CrossRefPubMed Metlay JP, Fishman NO, Joffe M, Edelstein PH: Impact of pediatric vaccination with pneumoccal conjugate vaccine on the risk of bacteremic pneumococcal pneumonia in adults. Vaccine. 2006, 24: 468-475. 10.1016/j.vaccine.2005.07.095.CrossRefPubMed
22.
go back to reference McIntosh ED, Conway P, Willingham J, Lloyd A: The cost-burden of paediatric pneumococcal disease in the UK and the potential cost-effectiveness of prevention using 7-valent pneumococcal conjugate vaccine. Vaccine. 2003, 21: 2564-2572. 10.1016/S0264-410X(03)00031-8.CrossRefPubMed McIntosh ED, Conway P, Willingham J, Lloyd A: The cost-burden of paediatric pneumococcal disease in the UK and the potential cost-effectiveness of prevention using 7-valent pneumococcal conjugate vaccine. Vaccine. 2003, 21: 2564-2572. 10.1016/S0264-410X(03)00031-8.CrossRefPubMed
23.
go back to reference Rudan I, Boschi-Pinto C, Biloglav Z, Mulholland K, Campbell H: Epidemiology and etiology of childhood pneumonia. Bull World Health Organ. 2008, 86: 408-416. 10.2471/BLT.07.048769.CrossRefPubMedPubMedCentral Rudan I, Boschi-Pinto C, Biloglav Z, Mulholland K, Campbell H: Epidemiology and etiology of childhood pneumonia. Bull World Health Organ. 2008, 86: 408-416. 10.2471/BLT.07.048769.CrossRefPubMedPubMedCentral
24.
go back to reference Marcos MA, Martínez E, Almela M, Mensa J, Jiménez de Anta MT: New rapid antigen test for diagnosis of pneumococcal meningitis. Lancet. 2001, 12: 1499-1500.CrossRef Marcos MA, Martínez E, Almela M, Mensa J, Jiménez de Anta MT: New rapid antigen test for diagnosis of pneumococcal meningitis. Lancet. 2001, 12: 1499-1500.CrossRef
25.
go back to reference Department of Statistics: Population and housing census statistics of Malaysia 2000. 2001 Department of Statistics: Population and housing census statistics of Malaysia 2000. 2001
26.
go back to reference Department of Statistics: Population distribution by authority areas and mukims. Population and housing census of Malaysia. 2000 Department of Statistics: Population distribution by authority areas and mukims. Population and housing census of Malaysia. 2000
27.
go back to reference Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, Elvin L, Ensor KM, Hackell J, Siber G, Malinoski F, Madore D, Chang I, Kohberger R, Watson W, Austrian R, Edwards K: Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J. 2000, 19: 187-195. 10.1097/00006454-200003000-00003.CrossRefPubMed Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, Elvin L, Ensor KM, Hackell J, Siber G, Malinoski F, Madore D, Chang I, Kohberger R, Watson W, Austrian R, Edwards K: Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J. 2000, 19: 187-195. 10.1097/00006454-200003000-00003.CrossRefPubMed
28.
go back to reference Siti Norbaya M, Rohani MY, Nordiah AJ: Antimicrobial susceptibility pattern and serotype distribution among clinical isolates of Streptococcus pneumoniae in Malaysia [poster]. 4th Asian Congress of Pediatric Infectious Disease (ACPID). 2008, Surabaya, Indonesia Siti Norbaya M, Rohani MY, Nordiah AJ: Antimicrobial susceptibility pattern and serotype distribution among clinical isolates of Streptococcus pneumoniae in Malaysia [poster]. 4th Asian Congress of Pediatric Infectious Disease (ACPID). 2008, Surabaya, Indonesia
29.
go back to reference Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, Reingold A, Cieslak PR, Pilishvili T, Jackson D, Facklam RR, Jorgensen JH, Schuchat A: Active Bacterial Core Surveillance of the Emerging Infections Program Network: Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. 2003, 348: 1737-1746. 10.1056/NEJMoa022823.CrossRefPubMed Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, Reingold A, Cieslak PR, Pilishvili T, Jackson D, Facklam RR, Jorgensen JH, Schuchat A: Active Bacterial Core Surveillance of the Emerging Infections Program Network: Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. 2003, 348: 1737-1746. 10.1056/NEJMoa022823.CrossRefPubMed
31.
go back to reference Low S, Chan FL, Cutter J, Ma S, Goh KT, Chew SK: A national study of the epidemiology of pneumococcal disease among hospitalized patients in Singapore: 1995 to 2004. Singapore Med J. 2007, 48: 824-829.PubMed Low S, Chan FL, Cutter J, Ma S, Goh KT, Chew SK: A national study of the epidemiology of pneumococcal disease among hospitalized patients in Singapore: 1995 to 2004. Singapore Med J. 2007, 48: 824-829.PubMed
33.
go back to reference World Health Organization: Making choices in health: WHO guide to cost-effectiveness analysis. 2003, Geneva: World Health Organization World Health Organization: Making choices in health: WHO guide to cost-effectiveness analysis. 2003, Geneva: World Health Organization
35.
go back to reference Whitney CG, Pilishvili T, Farley MM, Schaffner W, Craig AS, Lynfield R, Nyquist AC, Gershman KA, Vazquez M, Bennett NM, Reingold A, Thomas A, Glode MP, Zell ER, Jorgensen JH, Beall B, Schuchat A: Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet. 2006, 368: 1495-1502. 10.1016/S0140-6736(06)69637-2.CrossRefPubMed Whitney CG, Pilishvili T, Farley MM, Schaffner W, Craig AS, Lynfield R, Nyquist AC, Gershman KA, Vazquez M, Bennett NM, Reingold A, Thomas A, Glode MP, Zell ER, Jorgensen JH, Beall B, Schuchat A: Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet. 2006, 368: 1495-1502. 10.1016/S0140-6736(06)69637-2.CrossRefPubMed
36.
go back to reference Rückinger S, van der Linden M, Reinert RR, von Kries R: Efficacy of 7-valent pneumococcal conjugate vaccination in Germany: An analysis using the indirect cohort method. Vaccine. 2010, 28: 5012-5016. 10.1016/j.vaccine.2010.05.021.CrossRefPubMed Rückinger S, van der Linden M, Reinert RR, von Kries R: Efficacy of 7-valent pneumococcal conjugate vaccination in Germany: An analysis using the indirect cohort method. Vaccine. 2010, 28: 5012-5016. 10.1016/j.vaccine.2010.05.021.CrossRefPubMed
37.
go back to reference Zhou F, Shefer A, Kong Y, Nuorti JP: Trends in acute otitis media-related health care utilization by privately insured young children in the United States, 1997-2004. Pediatrics. 2008, 121: 253-260. 10.1542/peds.2007-0619.CrossRefPubMed Zhou F, Shefer A, Kong Y, Nuorti JP: Trends in acute otitis media-related health care utilization by privately insured young children in the United States, 1997-2004. Pediatrics. 2008, 121: 253-260. 10.1542/peds.2007-0619.CrossRefPubMed
39.
go back to reference Hooi LS, Lim TO, Goh A, Wong HS, Tan CC, Ahmad G, Morad Z: Economic evaluation of centre haemodialysis and continuous ambulatory peritoneal dialysis in Ministry of Health hospitals, Malaysia. Nephrology. 2005, 10: 25-32. 10.1111/j.1440-1797.2005.00360.x.CrossRefPubMed Hooi LS, Lim TO, Goh A, Wong HS, Tan CC, Ahmad G, Morad Z: Economic evaluation of centre haemodialysis and continuous ambulatory peritoneal dialysis in Ministry of Health hospitals, Malaysia. Nephrology. 2005, 10: 25-32. 10.1111/j.1440-1797.2005.00360.x.CrossRefPubMed
40.
go back to reference Isaacman DJ, Strutton DR, Kalpas EA, Horowicz-Mehler N, Stern LS, Casciano R, Ciuryla V: Impact of indirect (herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine. Clinical Therapeutics. 2008, 30 (8): 341-357.CrossRefPubMed Isaacman DJ, Strutton DR, Kalpas EA, Horowicz-Mehler N, Stern LS, Casciano R, Ciuryla V: Impact of indirect (herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine. Clinical Therapeutics. 2008, 30 (8): 341-357.CrossRefPubMed
41.
go back to reference Talbot TR, Poehling KA, Hartert TV, Arbogast PG, Halasa NB, Mitchel E, Schaffner W, Craig AS, Edwards KM, Griffin MR: Reduction in high rates of antibiotic-nonsusceptible invasive pneumococcal disease in Tennessee after introduction of the pneumococcal conjugate vaccine. Clin Infect Dis. 2004, 39: 641-648. 10.1086/422653.CrossRefPubMed Talbot TR, Poehling KA, Hartert TV, Arbogast PG, Halasa NB, Mitchel E, Schaffner W, Craig AS, Edwards KM, Griffin MR: Reduction in high rates of antibiotic-nonsusceptible invasive pneumococcal disease in Tennessee after introduction of the pneumococcal conjugate vaccine. Clin Infect Dis. 2004, 39: 641-648. 10.1086/422653.CrossRefPubMed
Metadata
Title
Impact of routine PCV7 (Prevenar) vaccination of infants on the clinical and economic burden of pneumococcal disease in Malaysia
Authors
Syed Aljunid
Gulifeiya Abuduxike
Zafar Ahmed
Saperi Sulong
Amrizal Muhd Nur
Adrian Goh
Publication date
01-12-2011
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2011
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-11-248

Other articles of this Issue 1/2011

BMC Infectious Diseases 1/2011 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.